Hansa Biopharma (BMV:HNSA N) - Cotización, noticias y análisis

Resumen de acción HNSA N

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.

Acerca de la empresa

HNSA N fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 56.9%

Análisis de riesgos

Acciones altamente ilíquidas

Los accionistas han sido diluidos en el último año

Competidores de Hansa Biopharma AB (publ)

Werewolf Therapeutics

NasdaqGS:HOWL

US$219.4m

Foghorn Therapeutics

NasdaqGM:FHTX

US$236.8m

Nanobiotix

ENXTPA:NANO

€300.1m

BioGend Therapeutics

TPEX:6733

NT$4.6b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Hansa Biopharma
Historical stock prices
Current Share Price	kr160.75
52 Week High	kr0
52 Week Low	kr0
Beta	0.97
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	HNSA N	MX Biotechs	Mercado MX
7D	0%	0%	0%
1Y	0%	0%	0%

Rentabilidad vs. Industria: HNSA N superó al sector MX Biotechs , que obtuvo un rendimiento del -9% el año pasado.

Rentabilidad vs. Mercado: HNSA N obtuvo unos resultados inferiores a los del mercado MX, que fue del 1.4% el año pasado.

Volatilidad de los precios

Is HNSA N's price volatile compared to industry and market?
HNSA N volatility
HNSA N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: HNSA N no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de HNSA N en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2007	159	Søren Tulstrup	www.hansabiopharma.com

Resumen de fundamentos de Hansa Biopharma AB (publ)

¿Cómo se comparan los beneficios e ingresos de Hansa Biopharma con su capitalización de mercado?
Estadísticas fundamentales de HNSA N
Capitalización bursátil	Mex$3.96b
Beneficios(TTM)	-Mex$1.08b
Ingresos (TTM)	Mex$237.08m

16.7x

Ratio precio-ventas (PS)

-3.7x

Ratio precio-beneficio (PE)

¿Está HNSA N sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HNSA N
Ingresos	kr148.44m
Coste de los ingresos	kr36.89m
Beneficio bruto	kr111.55m
Otros gastos	kr789.67m
Beneficios	-kr678.12m

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

Jul 20, 2023

Beneficios por acción (BPA)	-12.93
Margen bruto	75.15%
Margen de beneficio neto	-456.83%
Ratio deuda/patrimonio	192.4%

¿Cómo se ha desempeñado HNSA N a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción HNSA N

Recompensas

Análisis de riesgos

Competidores de Hansa Biopharma AB (publ)

NasdaqGS:HOWL

US$219.4m

NasdaqGM:FHTX

US$236.8m

ENXTPA:NANO

€300.1m

TPEX:6733

NT$4.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Recent updates

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021)

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021)

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

Senior VP recently bought Mex$694k worth of stock

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Hansa Biopharma AB (publ)

16.7x

-3.7x

Beneficios e Ingresos